Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

New generation DES present better results in vein grafts than older DES and BMS

There is little information comparing contemporary drug eluting stents (DES)  against bare metal stents (BMS), for PCI in saphenous vein grafts in patients receiving (CABG).

 New Generation DES Present Better Results in Vein Grafts than Older DES and BMS

This study aimed to assess clinical outcomes after PCI in saphenous vein grafts in patients receiving BMS, first generation DES, and new generation DES between 2006 and 2013. The study included inhospital events, and 30 day and one year mortality rates.

 

A total 15,003 patients received PCI in saphenous vein grafts during this period: 38% received BMS, 15% received first generation DES and 47% new generation DES.

 

Inhospital major adverse cardiovascular events was significantly lower in patients treated with new generation DES (OR, 0.51; CI 95%, 0.38–0.68; p<0.001) compared to those receiving older DES or BMS.


Also Read: “Second Generation DES Present Lower Mortality in Saphenous Vein Graft Lesions”.


 Similarly, 30 day (OR, 0.43; CI 95%, 0.32–0.59; p<0.001) and one year mortality (OR, 0.60; CI 95%, 0.51–0.71; p<0.001) were lower with new generation DES.

 

Conclusion

Patients receiving new generation DES in saphenous vein grafts present lower inhospital adverse events rate, and lower 30 day and one year mortality compared to first generation DES and BMS.

 

Editorial Comment

A significant number of vein grafts (10-40%) will be occluded in the first year and this will inexorable continue at a 2-5% annual rate, which accelerates as time goes by. The risk of reintervention and the technical difficulty to treat the native artery makes it necessary to treat vein grafts with PCI (it might even reach 10% of cases).

 

Several factors make this territory more challenging for PCI and there is no doubt that this disease is far more aggressive in vein grafts than in native arteries. This difficulty, however, does not affect the choice of device: new generation DES are also better in this territory.

 

Original title: Choice of Stent for Percutaneous Coronary Intervention of Saphenous Vein Grafts.

Reference: Javaid Iqbal et al. Circ Cardiovasc Interv. 2017;10:e004457.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...